Saint-Herblain (France), January 7, 2021 – Valneva SE (“Valneva” or “the Company”), a specialty vaccine company focused on prevention of infectious diseases with significant unmet medical need, today reported preliminary and unaudited cash and cash equivalents of €204.4 million at the end of December 2020, exceeding its guidance of between €180 million and €200 million.

Go here to read the rest:
Valneva Reports FY 2020 Cash of Over €200 Million

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *